Our goal:
Each year, millions suffer from cardiac arrest and hundreds of thousand of children suffer from neonatal asphyxia (lack of oxygen at birth). To minimise the harm from this, external or internal cooling is used, activating a detailed an highly regulated process in the body called mild hypothermic response. Our goal is to understand the genetic background of this response and use this to generate medications to manipulate this response.
Our Institutions and investors
All
-
Funding by Kría
On December 3rd 2025 it was announced that KALDUR therapeutics had obtained a funding offer from Kría – The New Business Venture Fund. The funding offer followed a funding round where 88 companies applied for funding and 22 were invited for further discussion, from which 11 were choosen for funding offer. The offer is contingent…
-
Funding by Rannís
On May 15th 2025, it was announced that The Icelandic Technology Development Fund managed by Rannís (The Icelandic Centre for Research) had awarded KALDUR Therapeutics 15 million ISK ( approx 100.000 EUR) for the project “A novel therapeutic target for preventing neurological damage after hypoxic brain injury” We are grateful to Rannis for the support…
-
Website launch
The website was launched in March 2025
KALDUR Therapeutics 